** Shares in Italy's Amplifon AMPF.MI drops as much as 27%, lowest since March 2020, after hearing aid maker cut FY outlook and posted Q2 core profit drop
** "The magnitude of underperformance is the key downside surprise and the market will need to see further datapoints before rebuilding confidence," J.P. Morgan says
** AMPF lowered its 2025 forecast, expects consolidated revenue growth of about 3%; it had previously expected growth in mid-to-high single-digit percentage range
** JPM also cut its FY25 EBITDA estimate by 8%, EPS by 15%
** Jefferies says Q2 numbers were well below expectations
** Barclays says "sizeable and broad-based miss will come as a disappointment and should also weigh on the entire hearing aid complex"
** However, Barclays "remain constructive on the longer-term story at AMP, and prefer Amplifon in the hearing aid space"
** Stock last down 23.8%; drops 38.6% YTD
(Reporting by Romolo Tosiani)
((Romolo.Tosiani@tr.com))